riluzole has been researched along with Friedreich Ataxia in 4 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Friedreich Ataxia: An autosomal recessive disease, usually of childhood onset, characterized pathologically by degeneration of the spinocerebellar tracts, posterior columns, and to a lesser extent the corticospinal tracts. Clinical manifestations include GAIT ATAXIA, pes cavus, speech impairment, lateral curvature of spine, rhythmic head tremor, kyphoscoliosis, congestive heart failure (secondary to a cardiomyopathy), and lower extremity weakness. Most forms of this condition are associated with a mutation in a gene on chromosome 9, at band q13, which codes for the mitochondrial protein frataxin. (From Adams et al., Principles of Neurology, 6th ed, p1081; N Engl J Med 1996 Oct 17;335(16):1169-75) The severity of Friedreich ataxia associated with expansion of GAA repeats in the first intron of the frataxin gene correlates with the number of trinucleotide repeats. (From Durr et al, N Engl J Med 1996 Oct 17;335(16):1169-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with spinocerebellar ataxia or Friedreich's ataxia (2:1 ratio) from three Italian neurogenetic units were enrolled in this multicentre, double-blind, placebo-controlled trial, and randomly assigned to riluzole (50 mg orally, twice daily) or placebo for 12 months." | 2.80 | Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. ( Casali, C; Coarelli, G; Ferraldeschi, M; Frontali, M; Leonardi, L; Marcotulli, C; Orzi, F; Petrucci, A; Piccolo, F; Ponzelli, F; Ristori, G; Romano, S; Salvetti, M; Spadaro, M; Vanacore, N; Vulpiani, MC, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Romano, S | 2 |
| Coarelli, G | 2 |
| Marcotulli, C | 1 |
| Leonardi, L | 1 |
| Piccolo, F | 1 |
| Spadaro, M | 1 |
| Frontali, M | 1 |
| Ferraldeschi, M | 1 |
| Vulpiani, MC | 1 |
| Ponzelli, F | 1 |
| Salvetti, M | 2 |
| Orzi, F | 1 |
| Petrucci, A | 1 |
| Vanacore, N | 2 |
| Casali, C | 1 |
| Ristori, G | 2 |
| Durr, A | 1 |
| Wood, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Riluzole in Hereditary Cerebellar Ataxia: a Randomized Double-blind Placebo-controlled Trial.[NCT01104649] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for riluzole and Friedreich Ataxia
| Article | Year |
|---|---|
Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Friedreich Ataxia; Humans; Ma | 2015 |
3 other studies available for riluzole and Friedreich Ataxia
| Article | Year |
|---|---|
Rare inherited diseases merit disease-specific trials.
Topics: Excitatory Amino Acid Antagonists; Female; Friedreich Ataxia; Humans; Male; Riluzole; Spinocerebella | 2015 |
Movement disorders: Repurposing riluzole to treat hereditary cerebellar ataxia.
Topics: Excitatory Amino Acid Antagonists; Female; Friedreich Ataxia; Humans; Male; Riluzole; Spinocerebella | 2015 |
Riluzole in patients with hereditary cerebellar ataxia - Authors' reply.
Topics: Cerebellar Ataxia; Friedreich Ataxia; Humans; Riluzole | 2016 |